Evidence map›Paper›PMID 40361347›Full record

ArticleCancers2025

Germline Testing in Breast Cancer: A Single-Center Analysis Comparing Strengths and Challenges of Different Approaches.

Monica Marabelli, Mariarosaria Calvello, Elena Marino, Chiara Morocutti, Sara Gandini, Matteo Dal Molin, Cristina Zanzottera, Sara Mannucci, Francesca Fava, Irene Feroce and 4 more

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Monica MarabelliDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.
Mariarosaria CalvelloDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.ORCID 0000-0003-2113-8503
Elena MarinoLaboratory of Medical Genetics, Cytogenetics and Molecular Genetics, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.
Chiara MorocuttiDepartment of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.ORCID 0009-0005-2852-2921
Sara GandiniDepartment of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.ORCID 0000-0002-1348-4548
Matteo Dal MolinLaboratory of Medical Genetics, Cytogenetics and Molecular Genetics, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.
Cristina ZanzotteraDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.
Sara MannucciDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.
Francesca FavaDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.
Irene FeroceDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.ORCID 0000-0001-9312-2020
Matteo LazzeroniDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.ORCID 0000-0002-2162-4002
Aliana Guerrieri-GonzagaDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.ORCID 0000-0003-1915-1688
Francesco BertoliniLaboratory of Medical Genetics, Cytogenetics and Molecular Genetics, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.ORCID 0000-0001-5660-3255
Bernardo BonanniDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.ORCID 0000-0003-3589-2128

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesCompared to single gene testing (SGT), multigene panel testing (MGPT) improves pathogenic variants (PVs) detection. However, MGPT yields complex results, including secondary findings, heterozygous PVs in recessive genes, low-penetrance PVs, and variants of uncertain significance. We reported our mono-institutional experience of germline testing in breast cancer (BC), comparing SGT and MGPT.

methodsWe retrospectively analyzed clinical and molecular data from 1084 BC patients: 308 underwent SGT (

resultsWe found ≥1 PV in 165 patients (165/1084 = 15.2%), including 91 in

conclusionsAlthough MGPT increases hereditary BC detection, its complexity requires clear guidelines for optimal clinical management and strategies for merging the benefits of SGT and MGPT.

Indexed as

breast cancergermline genetic testingmultigene panel testingprimary findingssecondary findingssingle gene testing

Identifiers

PMID40361347
PMCPMC12071043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.